BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Hairy cell leukemia (HCL) shows unique clinicopathological and biological features. HCL responds well to purine analogs but relapses are frequent and novel therapies are required. BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, including HCL-like leukem...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Pettirossi, Valentina, Santi, Alessia, Imperi, Elisa, Russo, Guido, Pucciarini, Alessandra, Bigerna, Barbara, Schiavoni, Gianluca, Fortini, Elisabetta, Spanhol-Rosseto, Ariele, Sportoletti, Paolo, Mannucci, Roberta, Martelli, Maria Paola, Klein-Hitpass, Ludger, Falini, Brunangelo, Tiacci, Enrico
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2015
主題:
Plenary Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4366655/
https://ncbi.nlm.nih.gov/pubmed/25480661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-10-603100
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料